Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Antibacterial therapeutics - Kane Biotech

Next Previous
Drug Profile

Antibacterial therapeutics - Kane Biotech

Alternative Names: Biofilm inhibitors - Kane Therapeutics; Dispersin B-based antibiofilm therapeutics - Kane Biotech; Dispersin B-based wound care therapeutics - Kane Biotech; Dispersin B/Gentamicin; DispersinB Topical wound gel; DispersinB-Gentamicin wound gel spray; Gentamicin/dispersin B

Latest Information Update: 31 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Medicine & Dentistry of New Jersey
  • Developer Kane Biotech
  • Class Aminoglycosides; Anti-inflammatories; Antibacterials; Enzymes; Proteins; Small molecules
  • Mechanism of Action Glycoside hydrolase stimulants; Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Bacterial infections
  • Research Wounds

Most Recent Events

  • 13 Mar 2025 Kane Biotech plans a phase I trial for Acne in 2025
  • 21 Nov 2024 Antibacterial therapeutics is still in preclinical phase for Bacterial infections (Prevention) in Canada (Kane Biotech website, November 2024)
  • 21 Nov 2024 Antibacterial therapeutics is still in preclinical phase for Bacterial infections in Canada (Kane Biotech website, November 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top